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Introduction 
Approximately 79 million Americans are currently infected with human papillomavirus (HPV), 
and 14 million more infections occur every year (Satterwhite et al., 2013).  Young adults 15-24 years of 
age account for about one-half of new HPV infections (Markowitz et al., 2014). The advent of HPV 
vaccines and resulting discourse in medical and public realms focused attention on this particular type 
of infection (Hudson, Rondinelli, Glenn, Peciado, & Chao, In Press). Vaccinations are in the forefront of 
patient-provider encounters due to current recommendations for vaccinating male and female 
patients. However, a paucity of literature restricts acquisition of knowledge, particularly in the college 
age patient. 
Background and Significance 
Cervical cancer, caused by oncogenic HPV genotypes, is the fourth leading cause of cancer 
among women worldwide (World Health Organization, 2015). In addition, HPV is the most common 
sexually transmitted diseases in the United States (Satterwhite et al., 2013).  Although HPV vaccines 
are a strong weapon against genital cancers, immunization rates among adolescents and young adults 
remain relatively low (Markowitz et al., 2014; Reagan-Steiner et al., 2015). Results from a 2014 
national survey of adolescent vaccination rates showed that HPV vaccine coverage rates were 60% for 
females and 40% for males; however, not all adolescents took the recommended three dose series 
conferring immunity (Centers for Disease Control and Prevention [CDC], 2014a; Reagan-Steiner et al., 
2015).  Falling short of the Healthy People 2020 goals for 80% immunizations, some 40% of females and 
22% of males received all three of the recommended doses (US Department of Health and Human 
Services, 2014).  
Of the more than 150 documented genotypes of HPV, approximately 40 affect the genital tract 
(Bernard et al., 2010). Using data from the HPV in Men (HIM) study, the prevalence of HPV in males 18 
to 70 years was estimated to be over 50%, with 6% caused specifically by HPV 16 (Giuliano et al., 2011). 
Persistent infections with HPV genotypes 16 and 18 cause approximately 70% of cervical cancers in 
females, and HPV 16 is also attributed to the majority of cases of anogenital, and some oropharyngeal, 
cancers in both sexes (International Agency for Research on Cancer [IARC], 2012). In a six-year 
Canadian study of 222 couples aged 18 to 24, evidence suggests that males, whose female partner had 
genital or oral HPV 16, were at risk for acquiring oral HPV 16 infections themselves (American 
Association of Cancer Research, 2014). Genital warts, which are highly infectious but not pre-
cancerous, are caused primarily by HPV genotypes 6 and 11, and some 500,000 cases occur among 
sexually active men and women annually (CDC, 2011b; CDC, 2012).  
Burden of HPV Infection 
The economic burden of direct medical costs associated with HPV-related cancers in the U.S. is 
estimated at $1.4 billion per year (Chesson et al., 2012). Some $300 million per year is spent on genital 
warts and $200 million per year on recurrent respiratory papillomatosis (RRP), a rare disease caused by 
HPV 6 and 11 that is characterized by the growth of wart-like tumors in the respiratory tract (Lacey, 
Lowndes, & Shah, 2006; National Institute on Deafness and Other Communication Disorders, 2010).  
Despite a number of treatment strategies, including surgical excision, the underlying cause of 
HPV is incurable as no antiviral therapy exists (CDC, 2012). In addition to medical costs, having a HPV 
infection negatively affects emotional, social, and sexual functioning. Many young adults report a 
decline in self-esteem, a negative body image, and the fear of disclosure to sexual partners (Fleurence, 
Dixon, Milianova, & Beusterien, 2007). 
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HPV Vaccination 
Because of limited access to vaccination records after high school, there is little actual 
information on HPV vaccination rates for young adults (Dempsey, Cohn, Dalton, & Ruffin, 2011).  One 
estimate is that sexually transmitted disease (STD) rates are the highest between the ages of 20 to 24 
years (CDC, 2014b). Although initial HPV infection may occur during adolescence or young adulthood, 
HPV-related cancers usually occur later in life; however, genital warts may occur as quickly as 0-5 
months after exposure to HPV genotypes 6 and 11 (Winer et al., 2005).  
A study in Australia of some 7000 patients over a 6 year time period reported the incidence of 
genital warts declined from 18.6% to 1.9% in females and from 22.9% to 2.9% in young males who were 
vaccinated against HPV (Read et al., 2011). Although appropriate vaccination for HPV effectively 
prevents cervical cancer and genital cancers, vaccinating both males and females has the potential to 
produce “herd” immunity by radically decreasing the rate of HPV transmission (Markowitz et al., 2014). 
To decrease the transmission of HPV through oral and genital contact, the quadrivalent HPV vaccine 
(4vHPV) was recommended for young women in 2006 (Markowitz et al., 2007) and for young males in 
2011 (CDC, 2011b). A bivalent HPV vaccine for females continues to be available, but the vaccine 
covers just two strains of HPV (16 and 18). The 4v HPV vaccine has a high rate of efficacy in both males 
and females, with estimated levels of immunity at 90% for females (Markowitz et al., 2007) and 89% for 
males (CDC, 2011b). Markowitz et al. (2016) found that 4vHPV prevalence (covered by the 4vHPV 
vaccine) decreased 64% among vaccinated females age 14 to 19 and 34% for those 20 to 24 years of 
age. 
In 2015, the Advisory Committee on Immunization Practices (ACIP) recommended the 9-valent 
HPV vaccine (9vHPV) as one of the vaccines available for routine immunization in males and females 
because it contains an additional five strains of HPV virus-like particles (VLPs) that cover anal cancers 
in males (Merck, 2015) and additional precancerous or dysplastic conditions of the genital tract 
(Petrosky et al., 2015). Efficacy rates for the 9v HPV vaccine are estimated at 96.5% (Petrosky et al., 
2015). 
The Centers for Disease Control and Prevention (2016) recommends that males and females 11-
12 years of age should receive either the 4vHPV vaccine or the 9-vHPV vaccine to prevent genital warts 
and genital and oral cancers. While the recommended age for initiating the vaccine series for males 
and females is between 11-12 years, the vaccine can be administered as early as age 9 years, and 
catch-up vaccination is recommended for up to the age of 26 years for females and 21 years for males. 
According to the CDC (2014a), because HPV antibody formation is strongest among school-aged 
children, the goal in vaccinating young boys and girls is to promote antibody formation prior to 
exposure to the HPV virus during sexual activity. If not vaccinated with the 4vHPV or the 9-vHPV at the 
recommended age, sexually active young adults can receive some benefit from HPV vaccines. This is 
because exposure to all HPV type vaccines is unlikely, so the vaccine protects for types to which the 
young adult has not been exposed (CDC, 2011a).  
Although the HPV vaccines have proven to be highly effective in adolescents and young adults 
age 16-26 years (Dahlstrom et al., 2012; Dempsey, Cohn, Dalton & Ruffin, 2011), there is limited data 
on the levels of immunization among college students, especially among young males (Katz, Krieger, & 
Roberto, 2011). Until recently, college students were not vaccinated as children against HPV because 
the vaccines were not available, accessible, or promoted by health professionals (McRee, Gilkey, & 
Dempsey, 2014) and parents for the most part did not want them (Gilkey, McRee, & Brewer, 2013).  
Although the current college population at urban campuses may have been eligible for the HPV vaccine 
as grade school or high school students, parents were required to grant permission, and parents may 
have declined administration of the vaccine for a variety of reasons. However, students 18 years and 
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older may give their own consent for the HPV vaccine and may be more receptive to receiving both 
HPV prevention education and HPV immunization.   
Racial Disparities in HPV 
Published data shows that racial disparities also exist.  Prevalence rates for non-Hispanic Black 
females aged 18 to 25 years is at 35%, versus 25% for non-Hispanic White peers (Harling, Subramanian, 
Barnighausen, & Kawachi, 2013: Manhart et al., 2006). In support of this, vaccination uptake data from 
the CDC in 2013-2014 showed that HPV vaccinations for adolescent females were lowest for non-
Hispanic Blacks, as compared to non-Hispanic whites, in initial immunization and completion of the 3-
dose series (CDC, 2013; Reagan et al., 2015). In adult women with cervical cancer, racial and ethnic 
disparities are pervasive with women of color disproportionately represented in both incidence and 
mortality (Ford, 2006; Harling et al., 2013). 
Purpose and Research Questions 
The purpose of this study was to describe the immunization knowledge, practices and 
prevention of HPV of a young adult population enrolled in an urban university. The urban college 
population selected provided a sample rich in racial and ethnic diversity. As such, data outcomes serve 
to inform the field of HPV immunization with meaningful data on various racial, ethnic, and sexual 
preference groups. Data and findings from this study will add to the limited knowledge about HPV 
immunization coverage in young adult men and women, especially among males of ethnic minorities. 
The project initiative is based on the recommendation of several studies that suggested that more 
information is needed on HPV immunization in young adults and that catch-up vaccination among males 
and females is important to decreasing the rate of HPV transmission (CDC, 2011b; CDC, 2016; Ford, 
2011).  
The research questions that guided the study were as follows: 
1. Is there a relationship between HPV knowledge and HPV immunization? 
2. Is there a relationship between HPV prevention behaviors and HPV immunization? 
3. Is there a difference between the HPV vaccination rates in a cohort of urban college 
students compared to the national HPV vaccination rates in males and females?  
4. Is there a difference between male and female students in HPV knowledge? 
5. Is there a difference between male and female students in HPV prevention behaviors? 
6. Is there a difference in HPV vaccination levels between young adults with health 
insurance and those without health insurance? 
Methods 
Setting and Sample 
The setting for this descriptive study was a large urban university located in the southwest that 
is rich in ethnic and racial diversity. This type of setting has provided samples in other studies that 
have been reported as underserved and disproportionately affected by genital warts and HPV-related 
cancers later in life (Ford, 2011; Gerend & Magloire, 2008; Liddon, Leichliter, & Markowitz, 2012). This 
study sample consisted of adolescents and young adults between the ages of 18 to 26 years who were 
enrolled in the university, could read English, and agreed to participate. A sample size of 500 was 
targeted with estimated power at 80% to detect a small effect size of d = .344 as significant.  The study 
was approved by the university’s institutional review board (IRB). 
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Data Collection 
Data were collected using an investigator-designed survey instrument developed at an 8th grade 
reading level. The items were predominately true or false. On four items, students choose among four 
or five levels of response options. The instrument consisted of questions eliciting demographic and 
personal information, 17 items on HPV knowledge, and 10 items on HPV prevention practices for males 
or 11 items for females (see Appendix A).  Item content was based on current research findings on HPV 
and vaccination for immunization. Four experts in the area of adolescent and young adult health 
reviewed the items for content relevancy and revised the items accordingly. A statistician was 
consulted to ensure suitability for statistical analysis.   
Student participation was voluntary and survey responses were anonymous. A recruitment 
poster was placed in a large area where students gathered between classes. A written invitation to 
participate was given to students, and investigators were available to answer questions regarding the 
study. Students could decline to participate with no penalty. Informed consent was obtained for study 
participants.  Over a two week period, three investigators recruited participants until 500 surveys had 
been completed.  Students completed the survey that had no student identifying information and 
placed it in a locked box separate from the written consents. A gift card was given to thank students 
for their participation.  
 A printed version of the survey instrument was developed for scanning data directly into an 
electronic database for statistical analysis. Data were considered as aggregate for analysis and did not 
reflect any individual’s response. After data was entered into the system for analysis, a back-up set of 
data was stored, and the paper surveys were shredded.  
Analysis 
Demographic and personal sexual history data were coded, and aggregate data were reported 
as frequencies and percentages. Descriptive statistics were calculated for each survey item response, 
and HPV knowledge and HPV prevention scores obtained.  Continuous variables were evaluated for 
approximation to normality.  A t-test for independent samples was used to compare HPV knowledge 
and HPV prevention scores between groups. Chi-square analysis was used to compare the HPV 
vaccination rate in the study sample with national rates of HPV vaccination and the percentage of the 
sample vaccinated against HPV in students with and without health insurance.  
Results 
Of the 500 surveys collected, data from 479 completed surveys were analyzed for a 95.8% 
return rate. Not all data equaled 100% because of missing responses to various items.  Sample 
demographic characteristics are summarized in Table 1.  The students age range was 18 to 26 years 
with a mean age of 20.02 years for males (n=174) and 20.30 years for females (n=295). Female 
respondents outnumbered the males at 58.5% and 34.5% respectively.  The sample respondents were 
mainly single (88%), more than half were college freshman and sophomores, and approximately 90% 
were non-smokers.  Most students were employed part time (49%) or not at all (37%), and about half 
(49.2%) had health insurance.  
The sample was largely non-White Hispanic or Latino (53.2%), followed by Black or African 
American (18.3%), Asian (0.9%), White non-Hispanic (6.5%), and of two or more races (5.0%). Sexual 
preference was mostly heterosexual with one to three lifetime partners, and the majority of students 
reported condom use as “always” or “75% of the time”. The percentage of males with 4 or more sexual 
lifetime partners (29.59%) was significantly higher than for females (17.38%; p = 0.0071).  
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Results of sexual history and prevention practices are shown in Table 2. Male participants 
(13.29%) were significantly more likely than females (6.87%) to be diagnosed with genital warts 
(p=0.0211). Females participants were more likely than the males to have had at least one dose of the 
HPV vaccine (p <0.0001).  Both genders were unsure if they had had three doses of the HPV vaccine. 
HPV vaccination rates among Hispanic and Black females in the sample were significantly higher than 
national rates (p < .0001), but insurance coverage did not correlate with vaccination rates.  
 
  
Table 1. Characteristics of the College Sample 
Mean Age Male Participants                              20.02 years 
Mean Age Female Participants                          20.30 years 
 n % 
Gender: Males 174 34.5 
Gender: Females 295 58.5 
Marital Status 
     Married 18 3.8 
     Single 444 88.1 
     Separated 1 0.2 
     Divorced  3 0.6 
     Living with a partner but single 13 2.6 
Level of Education 
     Freshman 191 37.9 
     Sophomore 122 24.2 
     Junior 106 21.0 
     Senior 53 10.5 
     Graduate Student 3 0.6 
Employment 
     Full time (40 hours/week or more)  49 9.7 
     Part time (less than 40 hours/week)  245 48.6 
     None  184 36.5 
Health Insurance 
     No 230 45.6 
     Yes 248 49.2 
Race/Ethnicity 
     White-non Hispanic or Latino 33 6.5 
     Non-White-Hispanic or Latino 268 53.2 
     Black/African American 93 18.3 
     American Indian/Alaskan Native 3 0.6 
     Asian  50 9.9 
     Two or more races  25 5.0 
     Unknown 8 1.6 
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Table 2. Sexual History and Prevention Practices 
 Male 
n 
Male 
Percent 
Female 
n 
Female 
Percent 
Sexual Preference:  
     Heterosexual 151 87.79 254 86.10 
     Homosexual 16 9.30 20 6.78 
     Bisexual 5 2.91 18 6.10 
     None preferred 0 0 3 1.02 
 
Number of Lifetime Sexual Partners 
     0 Partners 2 1.18 15 5.94 
     1 Partner 75 44.38 144 50.35 
     2 Partners 27 15.98 41 14.34 
     3 Partners 5 8.88 33 11.54 
     4 or more Partners 50 29.59 51 17.38 
 
Condom Use with Sexual Activity 
     Always 89 52.05 127 47.04 
     About 75% of the time 30 17.54 51 18.89 
     About 50% of the time 16 9.36 31 11.48 
     About 25% of the time 11 6.43 21 7.78 
     Never use condoms 25 14.62 40 14.81 
 
Smoking History 
     None 150 86.21 271 92.81 
     Less than 20 cigarettes/day 22 12.64 20 6.85 
     More than 20 cigarettes/day 2 1.15 1 0.34 
 
Have you had at least one dose of the HPV vaccine? 
     No 105 61.76 119 41.75 
     Yes 65 38.24 166 58.25 
 
Have you had three doses of the HPV vaccine? 
     No 76 44.19 124 42.32 
     Yes 24 13.95 93 31.74 
     Uncertain 72 41.86 76 25.94 
 
Female Participants Only: Had a Pap test in the past 2 years 
     No - - 185 62.7 
     Yes - - 110 21.8 
     
I was vaccinated against HPV in: 
     Grade School 8 4.73 13 4.69 
     High School 32 18.93 101 36.46 
     College 10 5.92 25 9.03 
     I don’t know when I was vaccinated 42 24.85 39 14.08 
     I don’t know if I was vaccinated 77 45.56 99 35.74 
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Table 2. Sexual History and Prevention Practices 
 Male 
n 
Male 
Percent 
Female 
n 
Female 
Percent 
Were you diagnosed with genital warts in the past? 
     No 23 13.29 20 6.87 
     Yes 150 86.71 271 93.13 
 
Where would you go first to find information about HPV? 
     Health care provider 94 56.97 191 67.73 
     Family Member 10 6.06 12 4.26 
     Internet 57 34.55 74 26.24 
     Friends 4 2.42 5 1.77 
 
I would get the HPV vaccine if it were available to me 
     No 150 87.21 251 88.38 
     Yes 22 12.79 33 11.62 
 
I would like more information on HPV 
     No 111 65.29 193 67.25 
     Yes 59 34.71 94 32.75 
 
Knowledge and Prevention Scores 
Overall, males had significantly higher mean prevention scores (84.05; p < .0001) than females 
(71.20). In females, the mean HPV prevention score was statistically significantly higher if vaccinated 
(79.60; p<0.0001), with the highest prevention mean occurring when all 3 HPV vaccinations had been 
received (83.89). The next highest mean score was in relation to uncertain if all three doses received 
(69.47), and the lowest mean was for females not receiving all three doses of HPV vaccine (63.11).  
Differences between responses by gender were not significant, except for specific knowledge 
items. Female participants were more likely to answer correctly the question regarding the possibility 
of HPV transmission by kissing an infected person (70.98%; p<0.0001), while male participants were 
more likely to answer the “some types of HPV can cause throat cancer” question correctly (64.53%; 
p=0.0093). Female participants were more likely to correctly answer “you must complete the 3-dose 
series for HPV vaccination” question (87.02%; p=0.0064). 
Discussion 
It is notable that the male participant vaccination rate was not significantly different than 
published rates; however, this may be a reflection of the timing of approval for HPV vaccines.  In the 
sample, male participants were more likely than females to be diagnosed for genital warts, possibly 
because genital warts are more detectable on males than on females because of the female anatomy. 
The low percentage of females that had a Pap smear is consistent with new guidelines put forth by 
American College of Obstetricians and Gynecologists (2016) on age to initiate Pap smear screening.  
Insurance coverage for females in the sample was not a factor in completing the vaccination 
series. This suggests that insurance coverage is not a barrier to vaccination in this population. A high 
percentage of the male participants (41.86%) were uncertain if they had completed the vaccine series, 
with only 13.95% stated that they had. A lower percentage of female participants (25.94%) were 
uncertain of completing 3 doses of vaccine.  This suggests that clinicians should emphasize the 
importance of completing the 3 dose series to confirm immunity, even as “catch-up” among older 
adolescents and young adults of both genders. An example of the need for correct and adequate 
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education is that the sample participants indicated that they would not be willing to obtain the 
vaccination if available to them (87.21% of males and 88.38% of females).   
Much of the data reported in current literature on young adults and HPV were collected by 
means of on-line or mailed surveys. Use of these media often results in low response return rates. For 
example, Dillard and Spear (2010) in a sample of female college students had a response rate of 22%. In 
this study, because college health care clinic personnel directly distributed the survey instrument to 
students until the target sample size was reached, an extremely high return rate (95.8%) of completed 
questionnaires was achieved. Furthermore, recommendations for vaccination have been relatively 
recent (2006 for females and 2011 for males).  Thus, there was opportunity to provide the students 
with relevant information.  Health care personnel were available to answer questions and share 
information about HPV prevention and clinic services after students completed the survey. Various 
authors have noted that health care providers’ dispersal of information and recommendations make 
young adults more likely to accept the HPV vaccine (Dillard & Spear, 2010; Jones & Cook, 2008).  
Accurate and reliable data on young adults’ knowledge and preventive practices respective to 
HPV are necessary to determine the most appropriate approach to increasing HPV vaccination levels 
among young males and females to prevent spread of this disease. The study can also add to existing 
information on HPV vaccination among young adults, especially in relation to gender and ethnic 
considerations as the sample was largely female (58%) and of Non-White-Hispanic or Latino background 
(53%). Because some levels of significance were found in relation to the male responses, this 
information also adds to the existing knowledge base of male preferences and practices. 
Recommendations for Practice 
The number of respondents who did not complete the HPV 3-dose series, or did not know if 
they had, illustrates the need for health care providers to stress the importance of completing the 
three dose series. The emphasis needs to be on confirmation of immunity and barriers to returning to 
clinic for the second and third doses eliminated.  In addition, vaccination rates need to be increased 
among adolescents as per standard recommendations. One way to do so may be to explain the 
importance of HPV vaccination during annual well child examinations when the patient is covered by a 
parent’s insurance.  
Education about HPV disease, prevention practices, and treatment is an essential part of health 
care instruction for adolescents and young adults.  Discussions can occur when young patients present 
for any acute illness.  Clinicians should inform these patients and families about the cost of the 
vaccination series as well as insurance coverage or resources available to cover the costs. At the 
college health level, various health promotion initiatives can be promoted on the college campus that 
provide the opportunity for clinicians to reinforce the importance of prevention of sexually transmitted 
diseases and, specifically, HPV prevention practices and vaccine availability.  
The finding that male participants were more likely than female participants to have been 
diagnosed with genital warts may indicate that females did not have HPV or were not as readily 
diagnosed with HPV as their male counterparts.  To aid in diagnosis, healthcare providers need to 
educate female patients about self-examination for HPV lesions. Because self-identification of HPV may 
be more difficult for the female than in the male due to anatomy, healthcare provider should address 
self-identification measures as well as prevention methods for HPV.  
Conclusion 
This study provides essential data in regard to college age students’ knowledge about HPV and 
preventive sexual practices that help prevent HPV infection or transmission. Despite differences in 
knowledge levels between genders, a significant number of participants were either not vaccinated or 
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did not complete the 3-dose series. This data provides direction for healthcare providers to improve 
student’s knowledge on causes and preventive strategies, promote the completion of vaccination 
series, and focus on educational efforts to prevent the transmission of HPV.   
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Appendix A. HPV Knowledge Among Male and Female College Students 
Item  Correct 
Answer 
Male 
n 
Correct 
Answer 
Male 
Percent 
Correct 
Answer 
Female 
n 
Correct 
Answer 
Female 
Percent 
HPV is a virus 162 94.74 273 93.49 
HPV can cause genital warts 136 78.61 222 76.82 
Some types of HPV can cause cervical cancer in 
women 
149 85.63 259 89.62 
The HPV vaccination will protect me against HPV 125 72.25 198 68.99 
HPV is the most common sexually transmitted 
disease 
108 62.43 174 60.42 
I can get HPV by kissing an infected person 91 52.60 203 70.98 
The Pap test will detect HPV in females 128 74.42 211 73.52 
There is a blood test that detects HPV in males 26 15.12 56 19.58 
Some types of HPV can cause throat cancer 111 64.53 149 52.10 
Some types of HPV can cause cancer in men 136 78.61 210 72.66 
A person can have HPV and not know it 162 93.10 275 94.50 
HPV vaccines are recommended for both males 
and females 
154 90.06 244 85.92 
People infected with genital warts will get cancer 122 71.35 226 79.02 
A person must complete the HPV immunization 3-
dose series to be protected 
132 77.19 248 87.02 
People can be vaccinated against HPV up to the 
age of 26 years 
123 71.10 208 73.24 
Condom use prevents the transmission of HPV 137 79.65 224 78.32 
There is a medicine to cure HPV 94 55.29 170 59.65 
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